UNIQURE N.V.
uniQure NV (QURE) is a biotechnology company focused on developing and commercialising gene therapies using viral vector platforms, particularly adeno‑associated viruses (AAVs). The firm targets rare genetic disorders — including haemophilia and select neurological conditions — with the aim of delivering durable, potentially one‑time treatments rather than chronic medication. Its market capitalisation is approximately $3.89 billion, reflecting investor expectations around clinical progress and regulatory decisions. Key investor considerations include clinical trial outcomes, regulatory approvals, the complexity and cost of scaling viral‑vector manufacturing, and competition in the gene‑therapy space. Revenue today is limited and may depend on future product approvals, partnerships or licensing deals. Shares tend to be sensitive to trial readouts, filings and collaboration announcements, making them relatively volatile. This information is for educational purposes only and not personal financial advice; values can rise or fall and past performance is not a reliable guide to future results.
Stock Performance Snapshot
Analyst Rating
Analysts suggest buying uniQure NV's stock with a target price of $53.18, indicating strong growth potential.
Financial Health
uniQure NV is doing well, showcasing strong revenue and cash flow with impressive profit margins.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Discover More Opportunities
ACADIA PHARMACEUTICALS INC
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for central nervous system disorders.
ADAPTIVE BIOTECHNOLOGIES CORP
Adaptive Biotechnologies Corporation is a commercial-stage biotechnology company. The Company is focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed. It applies its platform to partner with biopharmaceutical companies, inform drug development, and develop clinical diagnostics across its two business segments: Minimal Residual Disease (MRD) and Immune Medicine. The MRD business focuses on the use of its sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. Its MRD business is comprised of its clonoSEQ clinical diagnostic test, offered to clinicians. The IM business focuses on the discovery and development of transformative immune-based therapies in the treatment of patients with cancer and autoimmune diseases.
ABCELLERA BIOLOGICS INC
AbCellera Biologics Inc is a biotechnology company that provides technology to discover and develop novel fully human monoclonal antibodies.
Baskets Featuring QURE
Gene Therapy's Regulatory Tailwind
Sarepta Therapeutics' stock surged after the FDA re-approved its gene therapy for muscular dystrophy, signaling a positive turn for the industry. This development creates a potential tailwind for other biotech companies specializing in novel treatments for rare genetic diseases.
Published: July 30, 2025
Explore BasketPioneers In Rare Disease Therapy
The FDA's approval of PTC Therapeutics' drug for the rare disorder PKU marks a significant advancement in metabolic disease treatment. This event creates an investment opportunity by highlighting the growth potential of other biopharmaceutical companies specializing in therapies for rare genetic conditions.
Published: July 29, 2025
Explore BasketCell & Gene Therapy Logistics
This carefully curated collection features companies providing the essential infrastructure that makes advanced cell and gene therapies possible. Selected by expert analysts, these stocks represent the "picks and shovels" of the biotech revolution—giving you exposure to regenerative medicine's growth without the direct risks of clinical trials.
Published: June 17, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Gene‑therapy focus
uniQure's core expertise is in AAV‑based gene therapy, which promises durable effects; however, clinical and manufacturing hurdles mean outcomes can vary.
Rare disease market
Targeting haemophilia and other rare conditions offers high unmet need and potential value, yet commercial uptake depends on pricing, reimbursement and long‑term data.
Regulatory milestones
Trial readouts and approval decisions drive valuation swings; these catalysts can create opportunities but also pose binary risks for investors.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.